Comparison · NCT02014519-9635d6e3
Female Group vs Male Group: Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Gender)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Female Group vs Male Group: Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Gender). Trial comparisons, record NCT02014519-9635d6e3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02014519-9635d6e3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.868 | 0.848 | 0.886 | wilson | |
| Risk in group 2 | 0.828 | 0.801 | 0.853 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0395 | 0.00758 | 0.0727 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 1.01 | 1.09 | log | |
| Odds ratio, group 1 over group 2 | 1.36 | 1.06 | 1.75 | log | |
| Number needed to treat, for one more participant with the outcome on Female Group than on Male Group | 25.3 | 13.8 | 132 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Female Group | Female subjects aged 18 years and above who had agreed to collection of blood sample. | 1,052 | 1,212 | OG000 |
| Group 2 | Male Group | Male subjects aged 18 years and above who had agreed to collection of blood sample. | 652 | 787 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Gender)
- Description
- Seronegativity was defined as anti-PT IgG levels under the sensitivity limit of the assay (≤ 0.3 OD units)
- Time frame
- At the time of enrollment of each subject (Day 0)
- Population
- The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary
- NCT number
- NCT02014519
- Phases
- NA
- Conditions
- Pertussis, Pertussis Vaccines
- Interventions
- Blood sampling, Data collection
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2018-12-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02014519?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02014519-9635d6e3